This disease is more infectious than HIV because it is very easily transmitted by blood and other body fluids.
Once infected with the hepatitis B virus, approximately 10% of the people develop a chronic permanent infection.
Hepatitis B is very common in Asia, China, Philippines, Africa and the Middle East. The overall incidence of reported hepatitis B cases is 2 per 10,000 individuals, but the true incidence may be higher, because many cases do not cause symptoms and go undiagnosed and unreported.
Most people do not experience any symptoms during the acute phase of hepatitis B. However, some people might develop symptoms like jaundice, dark urine, fatigue, nausea, vomiting and abdominal pain. The hepatitis B virus can also cause a chronic infection of the liver that can later develop into liver cirrhosis or liver cancer.
A positive blood test for the hepatitis B surface antigen (HBsAg) indicates that the person has an active hepatitis infection.
There is no specific treatment for acute hepatitis B. Bed rest along with adequate nutritional balance and replacement of fluids is recommended. Chronic hepatitis B can be treated with drugs, including interferon and antiviral agents.
Latest Publication and Research on Hepatitis B[50 years of hepatology - from therapeutic nihilism to targeted therapies]. - Published by PubMed
The Associated Ion between the VDR Gene Polymorphisms and Susceptibility to Hepatocellular Carcinoma and the Clinicopathological Features in Subjects Infected with HBV. - Published by PubMed
CpG ODN and ISCOMATRIX Adjuvant: A Synergistic Adjuvant Combination Inducing Strong T-Cell IFN-? Responses. - Published by PubMed
Relationship between HBV genotypes B, C and follicular helper T cells in patients with chronic hepatitis B and its significance. - Published by PubMed
Hepatitis B Virus Surface Antigen Selectively Inhibits TLR2 Ligand-Induced IL-12 Production in Monocytes/Macrophages by Interfering with JNK Activation. - Published by PubMed